COMMUNIQUÉS West-GlobeNewswire

CytoDyn to Present on Leronlimab Induction of PD-L1 and Immune Checkpoint Inhibitor Responses in Metastatic Triple-Negative Breast Cancer at the AACR Special Conference: Mechanisms of Cancer Immunity and Cancer-related Autoimmunity
25/09/2025
Company to deliver oral and poster presentations for data on leronlimab’s action on PD-L1 expression and patient survival in triple-negative breast cancer VANCOUVER, Washington, Sept. 25, 2025 (GLOBE NEWSWIRE) -- [...]
LB Pharmaceuticals Strengthens Board of Directors with Appointments of William Kane and Rekha Hemrajani
25/09/2025
NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX) today announced the appointments of William Kane and Rekha Hemrajani to its Board of Directors [...]
Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin
25/09/2025
HOUSTON, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) (“Moleculin” or the “Company”), a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat [...]
AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors
25/09/2025
Patent supports AIM’s strategy to expand international market protection, providing opportunities for licensing, collaborations, and long-term revenue growth Japan is the third-largest pharmaceutical market globally, [...]
Silexion Therapeutics Regains Compliance with Nasdaq Listing Requirements
25/09/2025
Company Successfully Meets Both Minimum Bid Price and Shareholders' Equity Requirements, Securing Continued Listing on the Nasdaq Capital Market GRAND CAYMAN, Cayman Islands, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Silexion [...]
Femasys Accelerates European Growth for FemBloc® with Kebomed Partnership
25/09/2025
-- Femasys leverages Kebomed’s pan-European distribution strength to drive adoption of FemBloc permanent birth control in France and Benelux, unlocking significant market access -- ATLANTA, Sept. 25, 2025 (GLOBE [...]
HealthEquity Strengthens Executive Leadership Team with Strategic Appointments to Drive Growth and Innovation
25/09/2025
New CMO and Sales Executive Join from Mastercard and EverQuote to Capitalize on Historic HSA Market Expansion DRAPER, Utah, Sept. 25, 2025 (GLOBE NEWSWIRE) -- HealthEquity , Inc. (Nasdaq: HQY), the nation’s largest [...]
Philips joins Optum Healthcare’s network as a preferred provider in the USA
25/09/2025
September 25, 2025 Philips’ ambulatory and diagnostic solutions and services are now available to 3.4 million Optum policyholders for enhanced outpatient cardiac monitoring Amsterdam, the Netherlands – Royal Philips ( [...]
Safety Shot Partners with Monarq Asset Management to Actively Manage BONK Holdings Treasury
25/09/2025
Institutional-Grade Asset Manager Retained to Monetize BONK Treasury, Generate Yield, and Preserve Shareholder Value SCOTTSDALE, AZ, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Safety Shot, Inc. (Nasdaq: SHOT) today announced a [...]
PharmAla Partners with Veridion Group as Exclusive Distributor in New Zealand
25/09/2025
TORONTO, Sept. 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“ PharmAla ” or the “ Company ”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of [...]
PCI Biotech update on future operations
25/09/2025
Oslo (Norway), 25 September 2025 – PCI Biotech (OSE:PCIB) today announces an update on the ongoing evaluation of its future operations. Reference is made to the announcement on 18th August 2025 regarding the [...]
Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy
25/09/2025
One dose of nex-z led to rapid, deep and durable TTR reductions, with mean reductions of at least 90% from baseline sustained through three years Stabilization or improvement in disease-related clinical measures [...]
EmblemHealth Commits $2 Million To Combat Food Insecurity in New York City
25/09/2025
EmblemHealth partners with local food charities through its 15 Neighborhood Care centers to battle hunger in the Big Apple NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- New York City's food pantries are struggling with [...]
Levicept to Present Key New Data from Phase II Trial of LEVI-04, a Novel Neurotrophin-3 Inhibitor, at ACR Convergence 2025
25/09/2025
A significant, dose-dependent reduction in bone marrow lesion presence and area was observed for LEVI-04 compared with placebo in patients with osteoarthritis Changes in bone marrow lesion area were significantly [...]
Back-to-School Season Brings Hidden Health Risk: New Portable Device Helps Families Navigate September's "Asthma Peak"
25/09/2025
AeroChamber2Go ® VHC Helps Ensure Kids Can Breathe Easy Anywhere – From Classroom to Soccer Field PLATTSBURGH, N.Y., Sept. 25, 2025 (GLOBE NEWSWIRE) -- While parents pack backpacks with pencils and notebooks this fall, [...]
First Patients Enrolled at UHealth – University of Miami in Aclarion’s Pivotal CLARITY Trial
25/09/2025
Enrollment remains on track with internal interim results expected in Q2 2026 Randomized study to evaluate Nociscan’s ability to improve surgical outcomes for chronic low back pain Nociscan aims to become the gold [...]
RetinalGenix Technologies Advances Home and Remote Monitoring Patent Portfolio, Positioning for the Future of Ocular and Systemic Disease Care
25/09/2025
APOLLO BEACH, Fla., Sept. 25, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. (OTCQB:RTGN) (“RetinalGenix” or the “Company”), a pioneering developmental-stage ophthalmic monitoring and biopharmaceutical company [...]
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine
25/09/2025
Peer-reviewed results from Phase 1b/2a Trial of Anti-pTau Active Immunotherapy from AC Immune Published in eBioMedicine Detailed results from completed Phase 1b/2a trial of ACI-35.030 and JACI-35.054 demonstrated that [...]
Algernon Announces CAD $4 Million Non-Dilutive Financing to Open Four Brain-Specific PET Scan Clinics in the U.S. for Early Stage Alzheimer’s Detection
25/09/2025
VANCOUVER, British Columbia, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Algernon Pharmaceuticals Inc. (the “Company” or “Algernon”) (CSE: AGN) (FRANKFURT: AGW0) (OTCQB: AGNPF), a Canadian healthcare company announces that it [...]

Pages